CORRECTION article

Front. Immunol., 16 May 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1611591

Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis

  • 1. The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China

  • 2. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

  • 3. Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China

  • 4. Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China

  • 5. Department of Esophageal Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China

In the published article, there was an error in Figure 3 and Figure 4 as published. The trend line visualization in the original Figure 3 was incomplete. The hierarchical annotation in the original Figure 4 erroneously uses the symbol “=” instead of “≥” for stratification labels. The corrected Figure 3 and Figure 4 and its caption

Figure 3

Figure 4

“Figure 3 Forest plot of subgroup analysis comparing the overall survival HR in patients who received PD-1/PD-L1 inhibitor-based therapy versus chemotherapy based on different PDL1 expression levels of CPS (A) and TPS (B).”

“Figure 4 Forest plot of subgroup analysis comparing the progression-free survival HR in patients who received PD-1/PD-L1 inhibitor-based therapy versus chemotherapy based on different PDL1 expression levels of CPS (A) and TPS (B).” appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

PD-1/PD-L1 inhibitor, esophageal squamous cell carcinoma, meta-analysis, immunotherapy, combined positive score

Citation

Ren W, Zhang H, Li Y, Sun W, Peng H, Guo H, Hou T, Wang M, Hu Z, Wu T and Liu B (2025) Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis. Front. Immunol. 16:1611591. doi: 10.3389/fimmu.2025.1611591

Received

14 April 2025

Accepted

06 May 2025

Published

16 May 2025

Volume

16 - 2025

Edited and reviewed by

Valentina De Falco, National Research Council (CNR), Italy

Updates

Copyright

*Correspondence: Baorui Liu, ; Tao Wu, ; Zhendong Hu,

†These authors share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics